Proprotein Convertase Subtilisin/Kexin 9 as a Modifier of Lipid Metabolism in Atherosclerosis

被引:5
作者
Poznyak, Anastasia V. [1 ]
Sukhorukov, Vasily N. [2 ]
Eremin, Ilya I. [3 ]
Nadelyaeva, Irina I. [3 ]
Gutyrchik, Nikita A. [3 ]
Orekhov, Alexander N. [2 ]
机构
[1] Inst Atherosclerosis Res, Osennyaya 4-1-207, Moscow 121609, Russia
[2] Russian Acad Med Sci, Inst Gen Pathol & Pathophysiol, Moscow 125315, Russia
[3] Petrovsky Natl Res Ctr Surg, 2 Abrikosovsky Lane, Moscow 119991, Russia
基金
俄罗斯科学基金会;
关键词
PCSK9; atherosclerosis; cardiovascular disease; CVD; lipids; lipid metabolism; LDL RECEPTORS; CARDIOVASCULAR EVENTS; PCSK9; INHIBITION; POOLED ANALYSIS; SAFETY; CHOLESTEROL; EVOLOCUMAB; EFFICACY; DEGRADATION; ALIROCUMAB;
D O I
10.3390/biomedicines11020503
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Despite being the most common treatment strategy in the management of atherosclerosis and subsequent cardiovascular disease, classical statin therapy has certain disadvantages, including numerous side effects. In addition, a regimen with daily administration of the drug is hard to comply with. Thus, there is a need for modern and more efficient therapeutic strategies in CVD treatment. There is extensive evidence indicating that PCSK9 promotes atherogenesis through a variety of mechanisms. Thus, new treatment methods can be developed that prevent or alleviate atherosclerotic cardiovascular disease by targeting PCSK9. Comprehensive understanding of its atherogenic properties is a necessary precondition for the establishment of new therapeutic strategies. In this review, we will summarize the available data on the role of PCSK9 in the development and progression of atherosclerosis. In the last section, we will consider existing PCSK9 inhibitors.
引用
收藏
页数:14
相关论文
共 50 条
  • [21] Proprotein convertase subtilisin kexin 9 (PCSK9) inhibitors to treat hypercholesterolemia: Effect on stroke risk
    Milionis, Haralampos
    Barkas, Fotios
    Ntaios, George
    Papavasileiou, Vasileios
    Vemmos, Kostantinos
    Michel, Patrick
    Elisaf, Moses
    EUROPEAN JOURNAL OF INTERNAL MEDICINE, 2016, 34 : 54 - 57
  • [22] Inhibition of proprotein convertase subtilisin/kexin type 9. Identifying the patients with diabetes that would benefit
    Mueller-Wieland, Dirk
    Brandts, Julia
    Marx, Nikolaus
    Schuett, Katharina
    DIABETOLOGE, 2019, 15 (01): : 30 - 38
  • [23] Proprotein convertase subtilisin/kexin type 9: from genetics to clinical trials
    Stoekenbroek, Robert M.
    Kastelein, John J. P.
    CURRENT OPINION IN CARDIOLOGY, 2018, 33 (03) : 269 - 275
  • [24] The challenges of proprotein convertase subtilisin-kexin-9 inhibitors for lipid guidelines and models of care
    Wierzbicki, Anthony S.
    CURRENT OPINION IN LIPIDOLOGY, 2017, 28 (06) : 470 - 476
  • [25] Proprotein convertase subtilisin/kexin type 9 inhibitors for reduction of cardiovascular events
    Turgeon, Ricky D.
    Pearson, Glen J.
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2018, 75 (11) : 747 - 754
  • [26] Recent advance in lipid management: Focus on PCSK9I (Proprotein Convertase Subtilisin/Kexin 9 Inhibitors)
    Kalra, Sanjay
    JOURNAL OF THE PAKISTAN MEDICAL ASSOCIATION, 2016, 66 (09) : 1191 - 1193
  • [27] Role of Insulin in the Regulation of Proprotein Convertase Subtilisin/Kexin Type 9
    Miao, Ji
    Manthena, Praveen V.
    Haas, Mary E.
    Ling, Alisha V.
    Shin, Dong-Ju
    Graham, Mark J.
    Crooke, Rosanne M.
    Liu, Jingwen
    Biddinger, Sudha B.
    ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2015, 35 (07) : 1589 - 1596
  • [28] Proprotein convertase subtilisin/kexin type 9-inhibition across different patient populations
    Stuerzebecher, Paulina Elena
    Laufs, Ulrich
    CURRENT OPINION IN LIPIDOLOGY, 2024, 35 (04) : 179 - 186
  • [29] Proprotein Convertase Subtilisin/kexin Type 9 Inhibition in Cardiovascular Prevention
    Ali, Ali
    Costanzo, Pierluigi
    Hoye, Angela
    CURRENT PHARMACEUTICAL DESIGN, 2018, 24 (04) : 442 - 450
  • [30] Pleiotropic effects of proprotein convertase subtilisin/kexin type 9 inhibitors?
    Filippatos, Theodosios D.
    Christopoulou, Eliza C.
    Elisaf, Moses S.
    CURRENT OPINION IN LIPIDOLOGY, 2018, 29 (04) : 333 - 339